Yumi Park

Yumi Park

Auto-generated profile, based on publicly available information

Yumi Park

Center for Personalized Precision Medicine of Tuberculosis, Inje University College of Medicine, Busan, Korea

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in EBioMedicine
Verified
Journal Article
Open access
TSTaeksun Song
Taeksun Song
MLMyungsun Lee
Myungsun Lee
HJHan-Seung Jeon
Han-Seung Jeon
YPYumi Park
Yumi Park
LDLori E. Dodd
Lori E. Dodd
RCRay Y. Chen
Ray Y. Chen
Long-term linezolid use is limited by mitochondrial toxicity-associated adverse events (AEs). Within a prospective, randomized controlled trial of linezolid to treat chronic extensively drug-resistant tuberculosis, we serially monitored the translational competence of mitochondria isolated from peripheral blood of participants by determining the cytochrome c oxidase/citrate synthase activity ratio. We compared this ratio with AEs associated with mitochondrial dysfunction. Linezolid trough concentrations were determined for 38 participants at both 600 mg and 300 mg doses. Those on 600 mg had a significantly higher risk of AE than those on 300 mg (HR 3·10, 95% CI 1·23-7 · 86). Mean mitochondrial function levels were significantly higher in patients before starting linezolid compared to their concentrations on 300 mg (P = 0·004) or 600 mg (P < 0·0001). Increasing mean linezolid trough concentrations were associated with lower mitochondrial function levels (Spearman's ρ = - 0.48; P = 0.005). Mitochondrial toxicity risk increased with increasing linezolid trough concentrations, with all patients with mean linezolid trough > 2 μg/ml developing an AE related to mitochondrial toxicity, whether on 300 mg or 600 mg. Therapeutic drug monitoring may be useful to prevent the development of mitochondrial toxicity associated with long-term linezolid use.

14 January 2014 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
TSTaeksun Song
Taeksun Song
YPYumi Park
Yumi Park
Isdore Chola ShamputaIsdore Chola Shamputa
Isdore Chola Shamputa
SSSunghwa Seo
Sunghwa Seo
SLSun Young Lee
Sun Young Lee
SCSang‐Nae Cho
Sang‐Nae Cho
Summary: Rifampicin resistance, a defining attribute of multidrug‐resistant tuberculosis, is conferred by mutations in the β subunit of RNA polymerase. Sequencing of rifampicin‐resistant (RIF‐R) clinical isolates of Mycobacterium tuberculosis revealed, in addition to RIF‐R mutations, enrichment of potential compensatory mutations around the double‐psi β‐barrel domain of the β′ subunit comprising the catalytic site and the exit tunnel for newly synthesized RNA. Sequential introduction of the resistance allele followed by the compensatory allele in isogenic Mycobacterium smegmatis showed that these mutations respectively caused and compensated a starvation enhanced growth defect by altering RNA polymerase activity. While specific combinations of resistance and compensatory alleles converged in divergent lineages, other combinations recurred among related isolates suggesting transmission of compensated RIF‐R strains. These findings suggest nutrient poor growth conditions impose larger selective pressure on RIF‐R organisms that results in the selection of compensatory mutations in a domain involved in catalysis and starvation control of RNA polymerase transcription.

1 November 2018 in Cell
Verified
Journal Article
Open access
Yin Yao DongYin Yao Dong
Yin Yao Dong
HWHua Wang
Hua Wang
APAshley C.W. Pike
Ashley C.W. Pike
SCStephen A. Cochrane
Stephen A. Cochrane
SHSadra Hamedzadeh
Sadra Hamedzadeh
ECElisabeth P. Carpenter
Elisabeth P. Carpenter
Protein N-glycosylation is a widespread post-translational modification. The first committed step in this process is catalysed by dolichyl-phosphate N-acetylglucosamine-phosphotransferase DPAGT1 (GPT/E.C. 2.7.8.15). Missense DPAGT1 variants cause congenital myasthenic syndrome and disorders of glycosylation. In addition, naturally-occurring bactericidal nucleoside analogues such as tunicamycin are toxic to eukaryotes due to DPAGT1 inhibition, preventing their clinical use. Our structures of DPAGT1 with the substrate UDP-GlcNAc and tunicamycin reveal substrate binding modes, suggest a mechanism of catalysis, provide an understanding of how mutations modulate activity (thus causing disease) and allow design of non-toxic "lipid-altered" tunicamycins. The structure-tuned activity of these analogues against several bacterial targets allowed the design of potent antibiotics for Mycobacterium tuberculosis, enabling treatment in vitro, in cellulo and in vivo, providing a promising new class of antimicrobial drug.

17 October 2016 in ACS Infectious Diseases
Verified
Journal Article
Closed access
YPYumi Park
Yumi Park
APAngela Pacitto
Angela Pacitto
TBTracy Bayliss
Tracy Bayliss
LCLaura A. T. Cleghorn
Laura A. T. Cleghorn
ZWZhe Wang
Zhe Wang
HBHelena Ingrid Boshoff
Helena Ingrid Boshoff

10 October 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SOSangmi Oh
Sangmi Oh
YPYumi Park
Yumi Park
CECurtis A. Engelhart
Curtis A. Engelhart
JWJoshua B. Wallach
Joshua B. Wallach
DSDirk Schnappinger
Dirk Schnappinger
CIClifton Earl Barry, III
Clifton Earl Barry, III
Magnesium plays an important role in infection with Mycobacterium tuberculosis (Mtb) as a signal of the extracellular environment, as a cofactor for many enzymes and as a structural element in important macromolecules. Raltegravir, an antiretroviral drug that inhibit HIV-1 integrase is known to derive its potency by selective sequestration of active site magnesium ions in addition to binding to a hydrophobic pocket. In order to determine if essential Mtb related phosphoryl transfers could be disrupted in a similar manner, a directed screened of known molecules with integrase inhibitor like pharmacophores (N-alkyl-5-hydroxypyrimidinone carboxamides) was performed. Initial hits afforded compounds with low micromolar potency against Mtb, acceptable cytotoxicity and PK characteristics and robust SAR. Elucidation of the target of these compounds revealed that they lacked magnesium dependence and instead disappointingly inhibited a known promiscuous target in Mtb DprE1 (Rv3790, decaprenylphosphoryl-β-D-ribose 2′-oxidase).

14 August 2017 in ACS Chemical Biology
Verified
Journal Article
Closed access
JMJr. John P. Santa Maria
Jr. John P. Santa Maria
YPYumi Park
Yumi Park
LYLihu Yang
Lihu Yang
NMNicholas Murgolo
Nicholas Murgolo
MAMichael D. Altman
Michael D. Altman
PKPeter S. Kutchukian
Peter S. Kutchukian